Foreign exchangemixed · 5 filings
“We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.”10-Q · Jul 30, 2026 ↗
Guardant Health, Inc.
GH
Market read
Guardant Health, Inc.'s current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 19 directly disclosed connections are confirming.
What changed
- Revenue increased 48.3% versus the comparable filing period.
- The operating loss widened by 10.3M.
Company-2.5% todayVolume comparison unavailable
Market group0 of 9 activeHigh-Beta Growth · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- GH's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if GH's group or a disclosed connection begins moving with it.
Research brief
The story so far
The latest filing evidence is available. 0 of 9 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 19 directly disclosed connections are confirming.
Evidence that supports
- Revenue increased 48.3% versus the comparable filing period.
Evidence that challenges
- The operating loss widened by 10.3M.
- Operating cash flow remained negative at -65.6M.
What would clarify the read
- GH's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations327
Usable filing statements138
Verified relationships13
Evidence supporting the case
- Latest annual revenue changed +32.9% year over year.
- Operating margin changed +15.5 percentage points in the latest annual period.
- Net margin changed +16.7 percentage points in the latest annual period.
Evidence challenging the case
- Diluted shares increased 2.1% in the latest annual period.
Questions before a position
- EV/sales is 247% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 10, 2026
158.826m+80.4%12m+167.2%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$373.7M+30.3%$-4.00+3.9%
2022-12-31$449.5M+20.3%$-6.41+0.9%
2023-12-31$563.9M+25.5%$-4.28+9.6%
2024-12-31$739.0M+31.0%$-3.56+9.6%
2025-12-31$982.0M+32.9%$-3.32+2.1%
What management says matters
Persistent and emerging business drivers
Restructuring and cost reductionsmixed · 5 filings
“As a result of the evaluation, the Company recorded an impairment of $ 18.6 million and $ 22.1 million for the years ended December 31, 2025 and 2023, respectively, for its non-marketable equity security investments, included in other income (expense), net on…”10-Q · Jul 30, 2026 ↗
Product pipeline and R&Dmixed · 1 filings
“This increase was related to commercial team expansion and marketing activities to support the Shield product launch and existing product growth, primarily resulting in an increase of $22.0 million in personnel costs, and an increase of $7.9 million in market…”10-Q · Oct 29, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 20.3× · EV/sales 21.4×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
158.82-2.5% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for GH. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment · baseline
The latest filing shows material pressure
10-Q filed 2026-05-07 against the comparable filing from 2025-04-30.
OperationsmixedEvidence score +1
liquiditycautiousEvidence score -1
valuationpremium
What improved
- Revenue increased 48.3% versus the comparable filing period.
What weakened
- The operating loss widened by 10.3M.
- Operating cash flow remained negative at -65.6M.
Filing receipts
“Non-marketable equity securities are recorded at cost, subject to periodic impairment reviews and adjustments for observable price changes from orderly transactions.”
“General and administrative expense Three Months Ended March 31, Change 2026 2025 $ % (unaudited) (in thousands) General and administrative expense $ 57,926 $ 46,952 $ 10,974 23 % General and administrative expenses were $57.9 million for the three months ended March 31, 2026, compared to $47.0 million for the three months ended March 31, 2025, an increase of $11.0 million, or 23%, primarily driven by an increase of $7.1 million in legal and other outside service costs, and $5.3 million in stock-based compensation.”
“Other income (expense), net Three Months Ended March 31, Change 2026 2025 $ % (unaudited) (in thousands) Other income (expense), net $ (157) $ 7,851 $ (8,008) (102) % Other income (expense), net was immaterial for the three months ended March 31, 2026, and was a $7.9 million income for the three months ended March 31, 2025, primarily attributable to a gain on extinguishment of convertible notes of $13.7 million related to the convertible notes exchange transaction completed in February 2025, partially offset by an impairment of $5.0 million recorded for one of our non-marketable equity security investments.”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Business ecosystem
The relationships behind GH
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMGNAmgen Inc.supplierFeb 19, 2026 ▾
“The MHLW additionally granted regulatory approval of the Guardant360 CDx liquid biopsy test as a companion diagnostic for identifying patients with metastatic NSCL cancer who may benefit from treatment with LUMAKRASTM (sotorasib), a KRAS G12C inhibitor develo…”
PANWPalo Alto Networks, Inc.partnerOct 29, 2025 ▾
“In addition, our Redwood City, San Diego and Palo Alto, California laboratories are currently operated as centers for our research and technology development, and our Palo Alto laboratory is also CLIA licensed.”
Depended on by
BLLNBillionToOne, Inc.competitorMar 11, 2026 ▾
“In the oncology market, our main competitors for our therapy selection and response monitoring tests include Caris Life Sciences, Inc., Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc., Guardant Health, Inc., NeoGenomics Laboratories, Inc…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 20 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
GH is currently a Follower in the organic co-movement group High-Beta Growth. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.